NEW YORK, Feb 15 - Aurora Biosciences said Thursday its fourth-quarter revenue slipped 17 percent to $16.5 million, compared with $19.9 million in the year ago period. 

The San Diego-based company did not offer a reason why its revenues dropped but noted that it generated revenues from such deals as an exclusive collaboration with Senomyx to develop consumer products that enhance taste and olfaction, a licensing agreement with Deltagen, and an ion channel technology agreement with GlaxoSmithKline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.